— Know what they know.
Not Investment Advice

VCYT NASDAQ

Veracyte, Inc.
1W: -2.9% 1M: -5.0% 3M: +62.0% YTD: +31.2% 1Y: +135.7% 3Y: +98.5% 5Y: +52.0%
$55.65
+0.04 (+0.07%)
 
Weekly Expected Move ±6.7%
$49 $53 $57 $60 $64
NASDAQ · Healthcare · Medical - Diagnostics & Research · Alpha Radar Neutral · Power 50 · $4.4B mcap · 79M float · 1.56% daily turnover · Short 72% of daily vol
Smart Money Score
Moderate 50
Insider
Congress1 trades
ETF Holdings
Key Statistics
Market Cap$4.4B
52W Range22.92-60.91
Volume740,193
Avg Volume1,233,235
Beta1.93
Dividend
Analyst Ratings
14 Buy 6 Hold 1 Sell
Consensus Buy
Company Info
CEOMarc Stapley
Employees755
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2013-10-29
6000 Shoreline Court
South San Francisco, CA 94080
US
650 243 6300
About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Recent Insider Trades

NameTypeSharesPriceDate
EASTHAM KARIN S-Sale 3,200 $52.78 2026-06-18
EASTHAM KARIN S-Sale 529 $53.55 2026-06-18
EASTHAM KARIN A-Award 5,272 2026-06-11
JONES EVAN/ FA A-Award 5,272 2026-06-11
Shafer David Brent A-Award 5,272 2026-06-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms